Published in Blood Weekly, November 1st, 2001
A new clinical study demonstrated the emerging therapeutic value of the SC-I product for bone marrow stem cells which were expanded outside the body for the restoration of normal blood and immune system function in cancer patients. The multi-center study, conducted at Hackensack University Medical Center (HUMC), Loyola University Medical Center and the Southwest Texas Cancer Institute, included 31 adult subjects with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.